Tailong Pharmaceutical’s announcement on the progress of major matters planned by the controlling shareholder and the resumption of trading
Securities code: 600222 Securities abbreviation: Tailong Pharmaceutical Announcement number: 2025-063
Henan Tailong Pharmaceutical Co., Ltd.
Announcement on the progress of major events planned by the controlling shareholder and resumption of trading
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Securities trading suspension and resumption situation: applicable
As the controlling shareholder of Henan Tailong Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") Zhengzhou Tairong Industrial Investment Co., Ltd. (hereinafter referred to as the "Tairong Industrial Investment") has made significant progress in planning the company's share transfer, the company's relevant securities are suspended and resumed trading as follows:
Securities Agency Trading Suspension Begins Trading Suspension Ends Trading Suspension
Securities abbreviation Type of trading suspension and resumption Trading resumption date code Day Period Day
600222 Tailong Pharmaceutical A shares resume trading 2025/12/8 2025/12/9
1. Stock trading suspension
The company received a notice from its controlling shareholder Taiyong Industrial Investment on December 1, 2025. Taiyong Industrial Investment is planning a share transfer, which may lead to a change in the company's control. After the company applied to the Shanghai Stock Exchange, the company's stock (securities abbreviation: Tailong Pharmaceutical, stock code: 600222) will be suspended from trading on December 2, 2025 (Tuesday). The trading suspension is expected to be no more than 2 trading days. For details, please refer to the "Announcement of Henan Tailong Pharmaceutical Co., Ltd. on the Controlling Shareholder's Planning of Suspension of Trading on Major Matters" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) (Announcement No.: Lin 2025-061).
In view that the above matters are still in the advancement stage, the company does not expect to be able to resume trading from the opening of the market on December 4, 2025 (Thursday). After applying to the Shanghai Stock Exchange, the company's shares will continue to be suspended from the opening of the market on December 4, 2025 (Thursday), and the trading suspension is expected to continue for no more than 3 trading days. For details, please refer to the "Announcement of Henan Tailong Pharmaceutical Co., Ltd. on the Continuing Suspension of Trading by the Controlling Shareholder in Planning for Major Matters" (announcement number: Lin 2025-062) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn).
2. Progress of major events
On December 8, 2025, the company received a notice from the controlling shareholder Taeyong Industrial Investment that the matters planned by it that may lead to a change of control of the company have been agreed upon and signed with relevant parties. For details, please refer to the relevant announcement disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day.
3. Resumption arrangements
According to the "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 4 - Trading Suspension and Resumption" and other relevant regulations, after the company applies to the Shanghai Stock Exchange, the company's shares will resume trading from the opening of the market on December 9, 2025 (Tuesday).
The above-mentioned change of control matters still need to carry out necessary internal decisions and obtain the approval, approval, registration or consent of the competent regulatory authorities before they can be formally implemented. There is uncertainty about whether this change of control can be implemented. Investors are advised to make prudent decisions and pay attention to investment risks.
The company will continue to pay attention to the progress of the above matters and perform its information disclosure obligations in strict accordance with the provisions and requirements of relevant laws and regulations. Relevant information is subject to the company's announcements published on the Shanghai Stock Exchange website (www.sse.com.cn) and the company's designated information disclosure media "Shanghai Securities News" and "China Securities News".
Announcement is hereby made.
Board of Directors of Henan Tailong Pharmaceutical Co., Ltd.
December 9, 2025